Volume Alert - AZN 72.18 Astrazeneca Plc $AZN Hit a high today of 72.24 Closing the day 10:30 at 72.18 -0.67 -0.92% With a day low of 71.67 and a total volume of 961,372.
AZN Recent Posts: http://investorshangout.com/AstraZeneca-PLC-AZN-50195/
AZN Astrazeneca Plc Recent Headline News
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - 2 hrs 35 mins ago
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 205.95 (+3.33), PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.43 (-0.42), ABBV: 65.11 (+1.11)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - Mon Nov 17, 9:04AM CST
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.44 (-0.41)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.45 (+1.24), ACT: 246.54 (+2.77), F: 15.48 (+0.34), FB: 74.08 (-0.80), PFE: 30.32 (-0.02), AGN: 208.53 (+9.88), YHOO: 51.87 (+0.12), PBR: 9.35 (-0.60), DFS: 65.27 (+0.29), DTSI: 32.47 (-0.56), SPY: 204.37 (+0.13), LNKD: 222.27 (-11.62), QQQ: 102.89 (-0.33), AME: 51.15 (-0.55), MRK: 59.53 (+0.46), AOL: 46.80 (+0.76), AZN: 72.44 (-0.41), GM: 32.41 (+0.62), CVEO: 10.51 (-0.13), DD: 70.43 (-0.37)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 72.44 (-0.41), MRK: 59.53 (+0.46), PFE: 30.32 (-0.02)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 72.44 (-0.41), LLY: 67.26 (-0.07), ABBV: 65.12 (+1.12), GSK: 45.85 (+0.11), SNY: 47.46 (+0.78), NVS: 94.43 (+0.48)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.32 (-0.02), AZN: 72.44 (-0.41), ABBV: 65.12 (+1.12)
AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting
Business Wire - Sun Nov 16, 8:00AM CST
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol. The results show that approximately twice as many patients met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6, compared to those treated with allopurinol alone. The data was presented as a late-breaking presentation at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA.
AZN: 72.44 (-0.41)
FibroGen Looks Healthy Heading Into IPO
Don Dion - at Seeking Alpha - Fri Nov 14, 3:30PM CST
ITMN: 73.89 (-0.02), IPF: 21.60 (unch), AZN: 72.44 (-0.41), FGEN: 23.34 (+1.34)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 303.53 (-1.90), ISIS: 48.98 (-0.03), AZN: 72.44 (-0.41), SNY: 47.46 (+0.78)
Cramer sees Dow Chemical in "smart, aggressive buyback"
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:38AM CST
DPS: 70.33 (+0.23), JACK: 70.05 (-1.70), FLEX: 11.00 (-0.10), VIA: 74.75 (+1.41), AZN: 72.44 (-0.41), KMB: 113.54 (+0.89), DIS: 90.42 (-0.38), M: 61.59 (-0.46), DOW: 51.13 (-0.24)
A Dividend Growth Portfolio For New Investors And Retirees: '10 Stocks' UPDATED
Dividends#1 - at Seeking Alpha - Thu Nov 13, 8:32PM CST
PM: 87.21 (+0.93), LMT: 185.61 (-0.99), KMR: 98.99 (+2.03), KMB: 113.54 (+0.89), ED: 62.52 (+0.49), AZN: 72.44 (-0.41), MCD: 95.78 (-0.43), MO: 49.04 (+0.26), O: 46.03 (+0.33), SO: 46.98 (+0.34)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.27 (+0.11), AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44), AMAG: 34.93 (+0.93)
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 204.37 (+0.13), AZN: 72.44 (-0.41), IBB: 289.25 (+1.08), CBLI: 0.40 (unch)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST
PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.44 (-0.41), BIND: 10.31 (+0.05)
AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent
Business Wire - Thu Nov 13, 6:00AM CST
AstraZeneca (NYSE: AZN) today announced that it has begun a pre-clinical development program to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations such as urgent surgery, or in the event of major bleeding. MEDI2452 is being developed by MedImmune, AstraZeneca's biologics research and development arm.
B: 37.16 (-0.14), AZN: 72.44 (-0.41)
Advaxis submits IND for HPV-associated cancers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 10:13AM CST
ADXS: 3.00 (+0.01), AZN: 72.44 (-0.41)
Look for Shares of AstraZeneca to Potentially Pullback after Yesterday's 1.35% Rise
Comtex SmarTrend(R) - Tue Nov 11, 4:14PM CST
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $73.75 to a high of $74.36. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $73.49 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 72.44 (-0.41)
AstraZeneca Set to Possibly Pullback After Yesterday's Rally of 1.35%
Comtex SmarTrend(R) - Tue Nov 11, 4:14PM CST
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $73.75 to a high of $74.36. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $73.49 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 72.44 (-0.41)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.34 (-0.07), JNJ: 108.27 (+0.11), IDRA: 2.36 (-0.09), DERM: 16.34 (+0.29), MRK: 59.53 (+0.46), PFE: 30.32 (-0.02), AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44), GSK: 45.85 (+0.11), HSP: 58.33 (+0.05), NVS: 94.43 (+0.48), CELG: 104.39 (+0.34)
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - Tue Nov 11, 3:01PM CST
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44)
AZN Recent Posts: http://investorshangout.com/AstraZeneca-PLC-AZN-50195/
AZN Astrazeneca Plc Recent Headline News
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - 2 hrs 35 mins ago
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 205.95 (+3.33), PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.43 (-0.42), ABBV: 65.11 (+1.11)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - Mon Nov 17, 9:04AM CST
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.44 (-0.41)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.45 (+1.24), ACT: 246.54 (+2.77), F: 15.48 (+0.34), FB: 74.08 (-0.80), PFE: 30.32 (-0.02), AGN: 208.53 (+9.88), YHOO: 51.87 (+0.12), PBR: 9.35 (-0.60), DFS: 65.27 (+0.29), DTSI: 32.47 (-0.56), SPY: 204.37 (+0.13), LNKD: 222.27 (-11.62), QQQ: 102.89 (-0.33), AME: 51.15 (-0.55), MRK: 59.53 (+0.46), AOL: 46.80 (+0.76), AZN: 72.44 (-0.41), GM: 32.41 (+0.62), CVEO: 10.51 (-0.13), DD: 70.43 (-0.37)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 72.44 (-0.41), MRK: 59.53 (+0.46), PFE: 30.32 (-0.02)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 72.44 (-0.41), LLY: 67.26 (-0.07), ABBV: 65.12 (+1.12), GSK: 45.85 (+0.11), SNY: 47.46 (+0.78), NVS: 94.43 (+0.48)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.32 (-0.02), AZN: 72.44 (-0.41), ABBV: 65.12 (+1.12)
AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting
Business Wire - Sun Nov 16, 8:00AM CST
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol. The results show that approximately twice as many patients met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6, compared to those treated with allopurinol alone. The data was presented as a late-breaking presentation at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA.
AZN: 72.44 (-0.41)
FibroGen Looks Healthy Heading Into IPO
Don Dion - at Seeking Alpha - Fri Nov 14, 3:30PM CST
ITMN: 73.89 (-0.02), IPF: 21.60 (unch), AZN: 72.44 (-0.41), FGEN: 23.34 (+1.34)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 303.53 (-1.90), ISIS: 48.98 (-0.03), AZN: 72.44 (-0.41), SNY: 47.46 (+0.78)
Cramer sees Dow Chemical in "smart, aggressive buyback"
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:38AM CST
DPS: 70.33 (+0.23), JACK: 70.05 (-1.70), FLEX: 11.00 (-0.10), VIA: 74.75 (+1.41), AZN: 72.44 (-0.41), KMB: 113.54 (+0.89), DIS: 90.42 (-0.38), M: 61.59 (-0.46), DOW: 51.13 (-0.24)
A Dividend Growth Portfolio For New Investors And Retirees: '10 Stocks' UPDATED
Dividends#1 - at Seeking Alpha - Thu Nov 13, 8:32PM CST
PM: 87.21 (+0.93), LMT: 185.61 (-0.99), KMR: 98.99 (+2.03), KMB: 113.54 (+0.89), ED: 62.52 (+0.49), AZN: 72.44 (-0.41), MCD: 95.78 (-0.43), MO: 49.04 (+0.26), O: 46.03 (+0.33), SO: 46.98 (+0.34)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.27 (+0.11), AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44), AMAG: 34.93 (+0.93)
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 204.37 (+0.13), AZN: 72.44 (-0.41), IBB: 289.25 (+1.08), CBLI: 0.40 (unch)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST
PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.44 (-0.41), BIND: 10.31 (+0.05)
AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent
Business Wire - Thu Nov 13, 6:00AM CST
AstraZeneca (NYSE: AZN) today announced that it has begun a pre-clinical development program to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations such as urgent surgery, or in the event of major bleeding. MEDI2452 is being developed by MedImmune, AstraZeneca's biologics research and development arm.
B: 37.16 (-0.14), AZN: 72.44 (-0.41)
Advaxis submits IND for HPV-associated cancers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 10:13AM CST
ADXS: 3.00 (+0.01), AZN: 72.44 (-0.41)
Look for Shares of AstraZeneca to Potentially Pullback after Yesterday's 1.35% Rise
Comtex SmarTrend(R) - Tue Nov 11, 4:14PM CST
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $73.75 to a high of $74.36. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $73.49 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 72.44 (-0.41)
AstraZeneca Set to Possibly Pullback After Yesterday's Rally of 1.35%
Comtex SmarTrend(R) - Tue Nov 11, 4:14PM CST
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $73.75 to a high of $74.36. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $73.49 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 72.44 (-0.41)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.34 (-0.07), JNJ: 108.27 (+0.11), IDRA: 2.36 (-0.09), DERM: 16.34 (+0.29), MRK: 59.53 (+0.46), PFE: 30.32 (-0.02), AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44), GSK: 45.85 (+0.11), HSP: 58.33 (+0.05), NVS: 94.43 (+0.48), CELG: 104.39 (+0.34)
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - Tue Nov 11, 3:01PM CST
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44)
